Grifols Therapeutics LLC clinical trials

Acquired by Grifols, Jun 1, 2011 · source ↗

The registry lists 46 studies whose lead sponsor is Grifols Therapeutics LLC. 4 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 22, 2026.

Studies

Recruiting first, then most recently updated. Showing 46 of 46. All Grifols studies →

• A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)RecruitingNCT07555483Phase 3

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating PolyradiculoneuropathyRecruitingNCT07540221Phase 3

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin LymphomaRecruitingNCT05645107Phase 3

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin DeficiencyEnrolling by invitationNCT02796937Phase 3

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin DeficiencyCompletedNCT04722887Phase 1/2

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)CompletedNCT01983241Phase 3

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand DiseaseWithdrawnNCT02472665Phase 4

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and AscitesCompletedNCT03451292Phase 3

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary ImmunodeficiencyCompletedNCT04566692Phase 4

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral ImmunodeficiencyCompletedNCT04561115Phase 3

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)TerminatedNCT04547140Phase 2

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory OutpatientsTerminatedNCT04847141Phase 3

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)CompletedNCT04480424Phase 2

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE)CompletedNCT02870348Phase 1/2

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Participants With Congenital AfibrinogenemiaCompletedNCT02281500Phase 1/2

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• Alphanate in Immune Tolerance Induction TherapyTerminatedNCT03095287Phase 2

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participants With Alpha1-Antitrypsin DeficiencyCompletedNCT02870309Phase 1/2

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With Amyotrophic Lateral SclerosisCompletedNCT02872142Phase 2

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary ImmunodeficiencyCompletedNCT02806986Phase 3

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis ExacerbationsCompletedNCT02413580Phase 3

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• Study Evaluating IGSC 20% Flexible Dosing in Treatment-Experienced and Treatment-Naive Subjects With Primary ImmunodeficiencyWithdrawnNCT03814798Phase 3

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia GravisCompletedNCT02473965Phase 2

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary ImmunodeficiencyCompletedNCT02604810Phase 3

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• Anti-Hepatitis A Virus, Pharmacokinetics, and Safety of Immune Globulin (Human)CompletedNCT03351933Phase 4

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary BypassCompletedNCT02037555Phase 2

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia GravisCompletedNCT02473952Phase 2

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes MellitusTerminatedNCT02093221Phase 2

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin DeficiencyCompletedNCT02282527Phase 2/3

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial OcclusionCompletedNCT01222117Phase 2

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted before Grifols Therapeutics LLC became part of Grifols

• A Dose Escalation and Safety Study of Plasmin (Human) In Acute Lower Extremity Native Artery or Bypass Graft OcclusionCompletedNCT00418483Phase 1

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted before Grifols Therapeutics LLC became part of Grifols

• Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITPCompletedNCT00220727Phase 2

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted before Grifols Therapeutics LLC became part of Grifols

• Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple SclerosisCompletedNCT00220779Phase 2

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted before Grifols Therapeutics LLC became part of Grifols

• Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)CompletedNCT00220740Phase 3

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted before Grifols Therapeutics LLC became part of Grifols

• Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular DegenerationCompletedNCT00220805Phase 2

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted before Grifols Therapeutics LLC became part of Grifols

• Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic FibrosisCompletedNCT01684410Phase 2

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• Tetanus Immunization in Subjects With No Immunization History or With Tetanus Antibody Levels Below Protective LevelsTerminatedNCT00437671Phase 4

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted before Grifols Therapeutics LLC became part of Grifols

• A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke PatientsCompletedNCT01014975Phase 1/2

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted before Grifols Therapeutics LLC became part of Grifols

• A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary ImmunodeficiencyCompletedNCT00389324Phase 2

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted before Grifols Therapeutics LLC became part of Grifols

• Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary ImmunodeficiencyCompletedNCT01465958Phase 4

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• Comparison of Pharmacokinetic, Safety, Tolerability of Alpha-1 MP and Prolastin In Alpha1-antitrypsin Deficient AdultsCompletedNCT00295061Phase 3

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted before Grifols Therapeutics LLC became part of Grifols

• Deposition of Inhaled Prolastin in Cystic Fibrosis PatientsCompletedNCT00486837Phase 2

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted before Grifols Therapeutics LLC became part of Grifols

• Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE)CompletedNCT00263887Phase 2

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted before Grifols Therapeutics LLC became part of Grifols

• The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) DeficiencyCompletedNCT00301366Phase 3

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted before Grifols Therapeutics LLC became part of Grifols

• An Open-label, Single-Arm Study to Evaluate the Safety and Rabies Virus Antibody Titers of Intramuscularly Administered Rabies Immune Globulin (Human)CompletedNCT02139657Phase 1

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted after Grifols Therapeutics LLC became part of Grifols

• Safety and Pharmacokinetics of Alpha-1 Proteinase Inhibitor in Subjects With Alpha1-Antitrypsin DeficiencyCompletedNCT01213043Phase 2

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted before Grifols Therapeutics LLC became part of Grifols

• Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency PatientsCompletedNCT00220766Phase 3

  Sponsor listed in the registry: Grifols Therapeutics LLC · First submitted before Grifols Therapeutics LLC became part of Grifols